Go to content
UR Home

Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity

Stahl, Andreas ; Krohne, Tim U. ; Eter, Nicole ; Oberacher-Velten, Isabel ; Guthoff, Rainer ; Meltendorf, Synke ; Ehrt, Oliver ; Aisenbrey, Sabine ; Roider, Johann ; Gerding, Heinrich ; Jandeck, Claudia ; Smith, Lois E. H. ; Walz, Johanna M.


IMPORTANCE: Anti-vascular endothelial growth factor (VEGF) therapies are a novel treatment option in retinopathy of prematurity (ROP). Data on dosing, efficacy, and safety are insufficient. OBJECTIVE: To investigate lower doses of anti-VEGF therapy with ranibizumab, a substance with a significantly shorter systemic half-life than the standard treatment, bevacizumab. DESIGN, SETTING, AND ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons